Laddar populära aktier...
With two noteworthy deals in Q2, a comprehensive agreement for digital management with Pareto Busine...
Redeye returns with an update following Hoylu’s Q1 2024 report that was largely in line with our est...
Windon Energy Group meddelade den 3 juni år 2024 att bolaget har erhållit de första ordrarna på den ...
Redeye endorses today’s news that Egetis has received a “Promising Innovative Medicine (PIM) designa...
Redeye comments on Oncopeptides' Q1 report, which had few surprises in terms of financials.
Redeye reviews the Integrum case and provides a more clear-cut take on its longer-term outlooks.
Redeye saw a mixed Q1 report, as sales and gross margins did not deviate much from our expectations,...
Svedbergs Group has set the course to consolidate the European market for bathroom fittings, evolvin...
Redeye comments on the Q1 report 2024. The rest of 2024 is funded through the recent rights issue, i...
The Committee for Medicinal Products for Human Use (CHMP) of EMA recommends a full marketing author...
Q-linea and its distribution partners continue to advance pilot and tender process activities, which...
Redeye briefly comments on CLS’ rights issue. We pause our coverage.
Fågelinfluensa i USA kan leda till att pandemiförberedelser intensifieras.
Redeye comments on Freemelt’s Q1 results, which came in lower than expected in terms of sales due to...
No deliveries in Q1 compared to one Freemelt ONE expected Opex being kept under control despite inve...